secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUCELL CORP /DE/ (ICCC)
CIK:        0000811641
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001213900-24-097449
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmuCell reports Q3 2024 product sales up 11% to $6M; net loss narrows to $702k
-------------------------------------------------------------------------------

- Product sales $6M in Q3 2024 vs $5.4M in Q3 2023 (+11%); 9-month sales $18.7M (+51% YoY).
- Net loss $702k ($0.09/sh) vs $940k ($0.12/sh) in Q3 2023; 9-month loss $2.7M vs $4.6M.
- Gross margin improved to 26% of sales in Q3 2024 from 23% in Q3 2023.
- EBITDA turned positive to ~$119k in Q3 2024 from ($95k) in Q3 2023.
- Cash increased to $3.8M from $979K at Dec 31, 2023; no line of credit drawn.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/811641/000121390024097449/0001213900-24-097449-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/811641/000121390024097449/ea0221098-8k_immu.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-097449

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer